Abstract
Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 359-363 |
| Number of pages | 5 |
| Journal | Wounds |
| Volume | 16 |
| Issue number | 12 |
| State | Published - Dec 1 2004 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
Cymetra : A treatment option for refractory ulcers. / Levy, Daniel; Banta, Meggan R.; Charles, Carlos A.; Eaglstein, William H.; Kirsner, Robert.
In: Wounds, Vol. 16, No. 12, 01.12.2004, p. 359-363.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cymetra
T2 - A treatment option for refractory ulcers
AU - Levy, Daniel
AU - Banta, Meggan R.
AU - Charles, Carlos A.
AU - Eaglstein, William H.
AU - Kirsner, Robert
PY - 2004/12/1
Y1 - 2004/12/1
N2 - Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.
AB - Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.
UR - http://www.scopus.com/inward/record.url?scp=12444318572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12444318572&partnerID=8YFLogxK
M3 - Article
VL - 16
SP - 359
EP - 363
JO - Wounds
JF - Wounds
SN - 1044-7946
IS - 12
ER -